Methylmalonic Acidemia

Based on an internal strategic review and prioritization of its portfolio, Asklepios BioPharmaceutical Inc (AskBio) has decided to give all rights of methylmalonic acidemia (MMA) to Selecta Biosciences Inc (NASDAQ: SELB). MMA program includes gene therapy...

Genome editing company, LogicBio Therapeutics, plans to begin trading on the Nasdaq under the ticker symbol “LOGC.” The Company LogicBio develops medicines to treat rare diseases with the ;GeneRide platform. This technology is designed to precisely integrate corrective genes into a...